These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24658155)

  • 1. Minimal residual disease in breast cancer: in blood veritas.
    Siravegna G; Bardelli A
    Clin Cancer Res; 2014 May; 20(10):2505-7. PubMed ID: 24658155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detecting Plasma Tumor DNA in Early-Stage Breast Cancer-Letter.
    Kodahl AR; Pallisgaard N; Jylling AM; Cold S; Knoop AS; Ditzel HJ
    Clin Cancer Res; 2015 Aug; 21(15):3569. PubMed ID: 26240292
    [No Abstract]   [Full Text] [Related]  

  • 3. Detecting Plasma Tumor DNA in Early-Stage Breast Cancer--Reply.
    Beaver JA; Park BH
    Clin Cancer Res; 2015 Aug; 21(15):3570. PubMed ID: 26240293
    [No Abstract]   [Full Text] [Related]  

  • 4. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
    Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer.
    Sunami E; Vu AT; Nguyen SL; Giuliano AE; Hoon DS
    Ann N Y Acad Sci; 2008 Aug; 1137():171-4. PubMed ID: 18837943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer.
    Kamel AM; Teama S; Fawzy A; El Deftar M
    Tumour Biol; 2016 Jun; 37(6):7565-72. PubMed ID: 26684805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating free DNA: a new surrogate marker for minimal residual disease?
    Fehm T; Banys M
    Breast Cancer Res Treat; 2011 Nov; 130(1):119-22. PubMed ID: 21327462
    [No Abstract]   [Full Text] [Related]  

  • 8. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer.
    Chen X; Bonnefoi H; Diebold-Berger S; Lyautey J; Lederrey C; Faltin-Traub E; Stroun M; Anker P
    Clin Cancer Res; 1999 Sep; 5(9):2297-303. PubMed ID: 10499596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Breast cancer diagnostics based on extracellular DNA and RNA circulating in blood].
    Rykova EIu; Skvortsova TE; Hoffmann AL; Tamkovich SN; Starikov AV; Bryzgunova OE; Permiakova VI; Warnecke JM; Sczakiel G; Vlasov VV; Laktionov PP
    Biomed Khim; 2008; 54(1):94-103. PubMed ID: 18421914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
    Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
    Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular DNA in breast cancer: Cell-surface-bound, tumor-derived extracellular DNA in blood of patients with breast cancer and nonmalignant tumors.
    Rykova EY; Laktionov PP; Skvortsova TE; Starikov AV; Kuznetsova NP; Vlassov VV
    Ann N Y Acad Sci; 2004 Jun; 1022():217-20. PubMed ID: 15251963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant reduction of telomere repetitive sequences in plasma cell-free DNA for early breast cancer detection.
    Wu X; Tanaka H
    Oncotarget; 2015 Oct; 6(30):29795-807. PubMed ID: 26356673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsatellite alterations plasma DNA of primary breast cancer patients.
    Shaw JA; Smith BM; Walsh T; Johnson S; Primrose L; Slade MJ; Walker RA; Coombes RC
    Clin Cancer Res; 2000 Mar; 6(3):1119-24. PubMed ID: 10741742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action.
    Gu G; Fuqua SA
    Clin Cancer Res; 2016 Mar; 22(5):1034-6. PubMed ID: 26700205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
    Birkenkamp-Demtröder K; Nordentoft I; Christensen E; Høyer S; Reinert T; Vang S; Borre M; Agerbæk M; Jensen JB; Ørntoft TF; Dyrskjøt L
    Eur Urol; 2016 Jul; 70(1):75-82. PubMed ID: 26803478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients.
    Otsuji K; Sasaki T; Tanaka A; Kunita A; Ikemura M; Matsusaka K; Tada K; Fukayama M; Seto Y
    Breast Cancer Res Treat; 2017 Feb; 162(1):11-18. PubMed ID: 28039535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cell free DNA in breast oncology.
    Canzoniero JV; Park BH
    Biochim Biophys Acta; 2016 Apr; 1865(2):266-74. PubMed ID: 27012505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.
    Li Z; Guo X; Tang L; Peng L; Chen M; Luo X; Wang S; Xiao Z; Deng Z; Dai L; Xia K; Wang J
    Tumour Biol; 2016 Oct; 37(10):13111-13119. PubMed ID: 27449045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.
    Parisi C; Mastoraki S; Markou A; Strati A; Chimonidou M; Georgoulias V; Lianidou ES
    Clin Chim Acta; 2016 Oct; 461():156-64. PubMed ID: 27510924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.